Kiromic Biopharma Submits IND to FDA for CAR T-Cell Therapy Targeting Iso-Mesothelin

Retrieved on: 2021-05-25 16:38:32

Tags for this article:

Click the tags to see associated articles and topics

Kiromic Biopharma Submits IND to FDA for CAR T-Cell Therapy Targeting Iso-Mesothelin. View article details on hiswai:

Excerpt

NEW YORK – Kiromic Biopharma said on Tuesday it has submitted an investigational new drug application to the US Food and Drug Administration to ...

Article found on: www.precisiononcologynews.com